Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL325429 | 0.81 | MAOB (0.58) | CYP11B2CYP11B1MAOBMAOACES2 | |
| SCHEMBL29392929 | 0.81 | MAOB (0.58) | CYP11B2CYP11B1MAOBMAOACES2 | |
| SCHEMBL911253 | 0.81 | DGAT1 (0.60) | CYP11B2CYP11B1CES2CES1KDM4E | |
| SCHEMBL17645709 | 0.79 | DGAT1 (0.68) | CES2CES1KDM4EALDH1A1GLA | |
| SCHEMBL28069620 | 0.77 | CES2 (0.46) | CYP11B2CYP11B1CES2CES1KDM4E | |
| SCHEMBL17514843 | 0.77 | KMT2A (0.44) | CYP11B2CYP11B1GABRA1GABRG2GABRB3 | |
| SCHEMBL27442149 | 0.77 | SMN1; SMN2 (0.48) | CYP11B2CYP11B1CES2CES1KDM4E | |
| SCHEMBL7840274 | 0.76 | CES2 (0.50) | CYP11B2CYP11B1CES2CES1ALDH1A1 | |
| SCHEMBL392840 | 0.75 | SMN1; SMN2 (0.63) | CYP11B2KDM4EALDH1A1TSHRCASP1 | |
| SCHEMBL645757 | 0.75 | ALDH1A1 (0.54) | CYP11B2CYP11B1MAOBCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008323-B2 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2021-05-18 | — | — | US | disclosed |
| US-20180346468-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2018-12-06 | — | — | US | disclosed |
| EP-3374360-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | Mavalon Therapeutics Limited (GB) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017081483-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | MAVALON THERAPEUTICS LIMITED (GB) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346468-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM1, GRM2 | CYP11B2 854/4885CYP11B1 669/4885GABRA1 38/4885 |
| US-11008323-B2 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors | GRM3, GRM1, GRM2 | CYP11B2 854/4885CYP11B1 669/4885GABRA1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.